Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study inPatients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association

/in ,

Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association